Omission of Endocrine Therapy in Estrogen Receptor–Low, Early-Stage Breast Cancer In a study reported in the Journal of Clinical Oncology, Choong et al looked at whether the omission of endocrine therapy in patients with estrogen receptor–low (1%–10% on immunohistochemistry), early...

Study: Don't Quit HT, There Are Strong Overall Survival (OS) Benefits Shown for HR+ eBC Patients. #powerofhormonetherapy #endocrinetherapy
ascopost.com/news/april-2...